IMGN stock forecast
Our latest prediction for ImmunoGen, Inc.'s stock price was made on the Feb. 24, 2020 when the stock price was at 5.09$.
In the short term (2weeks), IMGN's stock price should underperform the market by -3.71%. During that period the price should oscillate between -11.15% and +13.03%.
In the medium term (3months), IMGN's stock price should underperform the market by -9.44%. During that period the price should oscillate between -42.51% and +28.26%.Get email alerts
Create a solid portfolio with IMGN
About ImmunoGen, Inc.
ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded in March 1981 and is headquartered in Waltham, MA.
At the moment the company generates 51M USD in revenues.
On its last earning announcement, the company reported a loss of -1.03$ per share.
The book value per share is 0.60$
Three months stock forecastFeb. 24, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|